=Pacific Biosciences (PACB) to be acquired by Illumina (ILMN) for $8.00/share

• Update Jan 02, 2020 NEW YORK – Gene sequencing company Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences. Antitrust authorities in the U.S. and U.K. had been scrutinizing the deal, the companies said. 
• Illumina would pay Pacific Biosciences $98 million for the terminated deal, which was announced in 2018 and had attracted scrutiny from antitrust authorities in the United States and UK, both the companies said in a joint statement.
  

*****

• Oct. 30: #1, 5; vol. 777K

Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln
With its acquisition of Pacific Biosciences, Illumina will be positioned to provide integrated workflows and novel innovations that bring together the best of both technologies to help researchers advance their discoveries faster and clinicians offer new tests economically. The transaction is subject to approval by the shareholders of Pacific Biosciences, as well as other customary closing conditions, including applicable regulatory approvals. Illumina expects to close the transaction in mid-2019.

Pacific Biosciences misses by $0.04, misses on revs;

Reports Q3 (Sep) loss of $0.19 per share, $0.04 worse than the S&P Capital IQ Consensus of ($0.15); revenues fell 22.9% year/year to $18.16 mln vs the $22.39 mln S&P Capital IQ Consensus.

Illumina (ILMN) will acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences' 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.

=Pacific Biosciences (PACB) reported earnings on Wed 2 May 2018 (a/h)

Pacific Biosciences misses by $0.01, misses on revs

• Reports Q1 (Mar) loss of $0.20 per share, $0.01 worse than the Capital IQ Consensus of ($0.19); revenues fell 22.1% year/year to $19.4 mln vs the $23.97 mln Capital IQ Consensus.

=Pacific Biosciences (PACB) reported earnings on Thur 2 Nov 2017 (a/h)

Pacific Biosciences reports EPS in-line, misses on revs; names Kathy Ordoez as Chief Commercial Officer 

• Reports Q3 (Sep) loss of $0.19 per share, in-line with the Capital IQ Consensus of ($0.19); revenues fell 6.3% year/year to $23.54 mln vs the $28.29 mln Capital IQ Consensus.
• Gross profit for the third quarter of 2017 was $8.2 million, resulting in a gross margin of 35%. 
• Pacific Biosciences also named Kathy Ordoez as Chief Commercial Officer (Previously held senior roles at Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance Technologies) 

=Pacific Biosciences of California (PACB) reported earnings on Wed 26 April 2017 (a/h)

MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Wednesday reported a loss of $23.9 million in its first quarter.

The Menlo Park, California-based company said it had a loss of 26 cents per share.

The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The maker of genetic analysis technology posted revenue of $24.9 million in the period.

Pacific Biosciences shares have increased 36 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $5.15, a fall of 50 percent in the last 12 months.